Inclusion Criteria:

          1. Aged ≥18 years

          2. Karnofsky performance status ≥70%

          3. Pathologically confirmed MPM

               1. Epithelioid or biphasic histologic diagnosis provided that ≥10% of the tumor
                  expresses MSLN by IHC analysis

               2. Patients with peritoneal mesothelioma with pleural involvement are eligible only
                  if there is radiographic and pathologic confirmation of mesothelioma in the
                  pleural cavity and ≥10% of the tumor expresses MSLN by IHC analysis.

          4. Previously treated with at least 1 treatment regimen

          5. Measurable or evaluable disease (disease is considered evaluable but not measurable if
             it does not meet the eligibility criteria for mRECIST but is a manifestation of
             malignancy that can be followed qualitatively as an indicator of disease progression
             or treatment response)

          6. Chemotherapy, targeted therapy, or radiotherapy must be completed at least 7 days
             before leukapheresis.

             a. CPI must be completed at least 21 days before leukapheresis.

          7. Chemotherapy, targeted therapy, or therapeutic radiotherapy must be completed at least
             14 days before administration of T cells.

               1. Palliative radiotherapy can be completed 2 days before lymphodepletion.
                  Immunotherapy with CPI must be completed at least 42 days before administration
                  of T cells.

        9. Any major thoracic (thoracotomy with lung or esophageal resection) or abdominal
        (laparotomy with organ resection) operation must have occurred at least 28 days before
        study enrollment. Patients who have undergone diagnostic VATS or laparoscopy can be
        included in the study.

        10. All acute toxic effects of any previous therapeutic or palliative radiotherapy,
        chemotherapy, or surgical procedures must have resolved to grade 1 (CTCAE v5.0).

        11. Lab requirements (hematology):

        a. Absolute neutrophil count ≥1.5 K/mcL b. Platelet count ≥100 K/mcL

        12. Lab requirements (serum chemistry):

        a. Bilirubin ≤1.5x upper limit of normal (ULN) b. Serum alanine aminotransferase and serum
        aspartate aminotransferase (ALT/AST) level ≤5x ULN c. Serum creatinine level ≤1.5x ULN or
        creatinine >1.5x ULN but calculated clearances of >60 by Cockcroft-Gault Equation

        13. Negative screen for infectious disease markers including Hepatitis B core antibody,
        Hepatitis B surface antigen, Hepatitis C antibody, HIV 1-2 antibody, HTLV 1-2 and Syphilis
        (rapid plasma regain profile) Note - Patients with history of prior hepatitis B virus (HBV)
        infection are eligible if the HBV viral load is undetectable. Patients with a history of
        hepatitis C virus (HCV) infection who were treated for hepatitis C and cured are eligible
        if hepatitis C viral load is undetectable.

        14. Life expectancy at the time of screening ≥4 months

        Exclusion Criteria:

          1. Patients receiving therapy for concurrent active malignancy

             a. Patients receiving treatment for in situ skin malignancies are not excluded.

          2. Patients who received prior CAR T-cell therapy

          3. Untreated or active central nervous system (CNS) metastases (progressing or requiring

          4. anticonvulsants or corticosteroids for symptomatic control). Patients with a history
             of treated CNS metastases are eligible if all the following criteria are met:

               1. Presence of measurable or evaluable disease outside of the CNS

               2. Radiographic demonstration of improvement upon completion of CNS-directed therapy
                  and no evidence of interim progression between completion of CNSdirected therapy
                  and the screening radiographic study

               3. Completion of radiotherapy ≥8 weeks before the screening radiographic study

               4. Discontinuation of corticosteroids and anticonvulsants ≥4 weeks before the
                  screening radiographic study

          5. History of seizure disorder

          6. Active autoimmune disease that has required systemic treatment in the past year (with
             use of disease-modifying agents, corticosteroids, or immunosuppressive drugs)

             a. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid
             replacement therapy for adrenal or pituitary insufficiency) is not considered a form
             of systemic treatment and is allowed.

          7. Patients who are receiving daily systemic corticosteroids that are above physiological
             doses for any reason or who are under immunosuppressive or immunomodulatory treatment

          8. Patients with the below cardiac conditions:

               1. New York Heart Association stage III or IV congestive heart failure

               2. Myocardial infarction ≤6 months before enrollment

               3. History of myocarditis

               4. Serious uncontrolled cardiac arrhythmia, unstable angina, or uncontrolled
                  infection

          9. Patients with left ventricular ejection fraction ≤40%

         10. Patients with active interstitial lung disease/pneumonitis or a history of
             interstitial lung disease/pneumonitis requiring treatment with systemic steroids

         11. Baseline pulse oximetry <90% on room air at the screening timepoint

         12. Pregnant or lactating women

             a. Subjects and their partners with reproductive potential must agree to use an
             effective form of contraception during treatment and for 1 year following treatment.

         13. Known active infection requiring antibiotic treatment 7 days before the start of
             treatment (Day 0). Note: treatment can be delayed at the discretion of the treating
             physician to allow the patient to recover from the infection.

         14. Administration of live, attenuated vaccine within 8 weeks before the start of
             treatment (Day 0) and for 100 days following treatment.

         15. Any other medical condition that, in the opinion of the PI, may interfere with a
             subject's participation in or compliance with the study

         16. Any patient deemed to be noncompliant by the study team for administration of a high
             risk treatment agent and for close follow-up after treatment as required by the
             protocol